Bioatla

Bioatla Current Assets

The Current Assets of Bioatla (BCAB) as of Nov 18, 2026 is 8.01 M USD. In the previous year, Current Assets was 51.23 M USD — a change of -84.36% (lower).

Current Assets

8.01 MUSD

YoY

-84.36%

Last updated:

Current Assets of Bioatla is 2025 8.01 M USD. Current Assets of Bioatla was 2024 51.23 M USD. It decreases by -84.36% lower compared to the previous year.

The Bioatla Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
12.66 M USD
Jan 1, 2019
4.51 M USD
Jan 1, 2020
240.68 M USD
Jan 1, 2021
247.29 M USD
Jan 1, 2022
220.43 M USD
Jan 1, 2023
116.41 M USD
Jan 1, 2024
51.23 M USD
Jan 1, 2025
8.01 M USD
The Bioatla Current Assets history
YEARCurrent AssetsYoY
8.01 MUSD-84.36%
51.23 MUSD-55.99%
116.41 MUSD-47.19%
220.43 MUSD-10.86%
247.29 MUSD+2.75%
240.68 MUSD+5,240.16%
4.51 MUSD-64.41%
12.66 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioatla stock

Current Assets of Bioatla is 8.01 M USD in 2025.

Current Assets of Bioatla changed from 51.23 M USD to 8.01 M USD, representing a -84.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Bioatla since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Bioatla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioatla

All Key Metrics — Bioatla